Explore the latest in osteoporosis from The JAMA Network, including recent guidelines for and advances in screening, management, and prevention of the disorder.
This study evaluates the relationship between bone mineral density and intracranial aneurysm.
This Medical Letter review summarizes safety concerns regarding proton pump inhibitors such as increased fracture risk, hypomagnesemia and QT prolongation, and acute interstitial nephritis.
This mixed longitudinal study assesses the acquisition of whole-body and skeletal site–specific bone mineral content relative to linear growth in a healthy, diverse, longitudinal cohort of children, adolescents, and young adults and tests for differences related to sex and African American race.
This Swedish cohort study investigates whether treatment with alendronate is associated with reduced risk of hip fracture among older patients using oral glucocorticoids.
This population-based cohort study examines the association of mental disorders and psychotropic medication use with fracture risk in routine clinical practice.
This controlled clinical trial explores whether testosterone treatment of older men with low testosterone improves their bone density and strength.
This cohort study uses national electronic medical record data from Hong Kong to compare risk of osteoporotic fracture among patients prescribed dabigatran or warfarin for newly diagnosed nonvalvular atrial fibrillation.
This cohort study evaluates whether sarcopenia and/or osteopenia are associated with 1-year mortality in an older trauma patient population.
This Viewpoint outlines the diagnostic approaches and treatment options to reduce risk of fracture among patients with osteoporosis.
This secondary analysis of a randomized clinical trial examines whether thiazide diuretics for hypertension are associated with reduced fracture risk in older adults.
This pharmacoepidemiology study uses Medicare Part D data to describe changes in use of prescription drugs associated with an increase in fracture risk before and after fragility fractures.
This randomized clinical trial compares the effects of subcutaneous abaloparatide vs placebo on risk of new vertebral and nonvertebral fractures in postmenopausal women with osteoporosis.